Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Kruppel-Like Transcription Factors. Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] Journal article | | Title | Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Kruppel-Like Transcription Factors. | | Author(s) | Hiroi T, Deming CB, Zhao H, Hansen BS, Arkenbout EK, Myers TJ, McDevitt MA, Rade JJ | | Institution | Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md; and Millennium Pharmaceuticals Inc, Cambridge, Mass. | | Source | Arterioscler Thromb Vasc Biol 2009 Aug 6. | | Abstract | OBJECTIVE: Impairment of the thrombomodulin-protein C anticoagulant pathway has been implicated in pathological thrombosis associated with malignancy. Patients who receive proteasome inhibitors as part of their chemotherapeutic regimen appear to be at decreased risk for thromboembolic events. We investigated the effects of proteasome inhibitors on endothelial thrombomodulin expression and function.
METHODS AND RESULTS: Proteasome inhibitors as a class markedly induced the expression thrombomodulin and enhanced the protein C activating capacity of endothelial cells. Thrombomodulin upregulation was independent of NF-kappaB signaling, a principal target of proteasome inhibitors, but was instead a direct consequence of increased expression of the Krüppel-like transcription factors, KLF2 and KLF4. These effects were confirmed in vivo, where systemic administration of a proteasome inhibitor enhanced thrombomodulin expression that was paralleled by changes in the expression of KLF2 and KLF4.
CONCLUSIONS: These findings identify a novel mechanism of action of proteasome inhibitors that may help to explain their clinically observed thromboprotective effects. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19661484 |
|
|
| |
| | |
|
